These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24809734)

  • 1. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
    Gabrusiewicz K; Liu D; Cortes-Santiago N; Hossain MB; Conrad CA; Aldape KD; Fuller GN; Marini FC; Alonso MM; Idoate MA; Gilbert MR; Fueyo J; Gomez-Manzano C
    Oncotarget; 2014 Apr; 5(8):2208-20. PubMed ID: 24809734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.
    Cortes-Santiago N; Hossain MB; Gabrusiewicz K; Fan X; Gumin J; Marini FC; Alonso MM; Lang F; Yung WK; Fueyo J; Gomez-Manzano C
    Oncotarget; 2016 Mar; 7(13):16146-57. PubMed ID: 26910374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
    Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
    J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.
    Xu CS; Wang ZF; Dai LM; Chu SH; Gong LL; Yang MH; Li ZQ
    J Transl Med; 2014 May; 12():148. PubMed ID: 24884636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
    Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
    Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype.
    Liu D; Martin V; Fueyo J; Lee OH; Xu J; Cortes-Santiago N; Alonso MM; Aldape K; Colman H; Gomez-Manzano C
    Oncotarget; 2010 Dec; 1(8):700-709. PubMed ID: 21321379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic approaches to malignant gliomas.
    Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
    Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
    Wick W; Wick A; Weiler M; Weller M
    Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophils promote the malignant glioma phenotype through S100A4.
    Liang J; Piao Y; Holmes L; Fuller GN; Henry V; Tiao N; de Groot JF
    Clin Cancer Res; 2014 Jan; 20(1):187-98. PubMed ID: 24240114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro.
    Shamshiripour P; Rahnama M; Nikoobakht M; Rad VF; Moradi AR; Ahmadvand D
    J Control Release; 2024 May; 369():128-145. PubMed ID: 38522817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.